The evaluation of effectiveness of dT vaccine on immune response to HB vaccine in non responder dialysis patients
Phase 2
Completed
- Conditions
- End Stage Renal Disease.ESRD
- Registration Number
- IRCT138812093454N1
- Lead Sponsor
- Isfahan University Of Medical Science
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Inclusion:1)age>=18yr,2)hemodialysis and peritoneal dialysis patients,3)comleted at least 3 dose HBV vaccine schedule and had HBS Ab <10
Exclusion:1)no compliance,2)renal transplant
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method HBS Ab titer. Timepoint: 1-2 m and 6 month after completing vaccination. Method of measurement: ELISA.
- Secondary Outcome Measures
Name Time Method --------. Timepoint: -----. Method of measurement: ------.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie dT vaccine enhancement of HBV seroconversion in ESRD non-responders?
How does dT vaccine adjuvant compare to standard HB vaccination protocols in dialysis patients' immune response?
Which biomarkers correlate with HBV vaccine responsiveness in IRCT138812093454N1 ESRD participants?
What adverse events are associated with dT vaccine administration in immunocompromised dialysis populations?
Are there synergistic adjuvant combinations with dT vaccine for improving HBV immunity in ESRD patients?